Mar-Cof CG Shortage: What Providers and Prescribers Need to Know in 2026

Patients prescribed Mar-Cof CG — the codeine phosphate/guaifenesin oral solution — are increasingly reporting difficulty filling their prescriptions at local pharmacies. While there is no active FDA-declared shortage as of 2026, a combination of structural factors has reduced the availability of this Schedule V controlled substance at many pharmacy locations.

This guide summarizes the clinical context, the reasons for access challenges, evidence-based therapeutic alternatives, and how providers can help patients navigate the system more effectively.

Clinical Overview of Mar-Cof CG

Mar-Cof CG (codeine phosphate 7.5 mg / guaifenesin 225 mg per 5 mL) is a Schedule V antitussive-expectorant combination indicated for the temporary relief of cough and chest congestion. It is manufactured by Marnel Pharmaceuticals, LLC and distributed by Allegis Pharmaceuticals, LLC. The formulation is alcohol-free and sugar-free, which is relevant for diabetic or alcohol-avoiding patients.

Codeine is a weak opioid agonist that requires CYP2D6 conversion to morphine for most of its antitussive and analgesic activity. Approximately 10% of the population are CYP2D6 poor metabolizers, for whom codeine may be ineffective. Conversely, ultra-rapid metabolizers (1–7% of the population) may reach dangerously high morphine levels even at standard doses — a critical safety consideration noted in the FDA labeling.

Why Patients Are Struggling to Fill Mar-Cof CG Prescriptions

The access challenges are structural rather than supply-chain-driven:

• Reduced pharmacy stocking. The DEA compliance overhead for Schedule V products leads many pharmacies to reduce or discontinue stocking low-volume codeine cough preparations. Independent and smaller pharmacies are more likely to have dropped these products entirely.
• Post-2018 FDA guidance. The FDA's 2018 recommendation against codeine use in patients under 18 reduced overall demand for codeine cough products, leading to lower stocking across the board even for adult-indicated formulations.
• State-level scheduling variances. Several states impose stricter scheduling than federal Schedule V for codeine cough preparations. In these states, the prescription requirements are more burdensome, further reducing pharmacy willingness to stock.
• Seasonal demand pressure. Pharmacies maintaining minimal codeine inventory may run out during peak respiratory illness seasons, particularly October through March.

Clinical Alternatives to Consider When Mar-Cof CG Is Unavailable

When Mar-Cof CG is unavailable, the following evidence-supported alternatives are worth considering based on the patient's clinical presentation:

• Benzonatate (100–200 mg TID): First-line prescription alternative for cough suppression. Non-opioid, not a controlled substance, widely available at most pharmacies. Mechanism: peripheral stretch receptor anesthesia in the lower respiratory tract. Key counseling: capsules must be swallowed whole; chewing causes dangerous oropharyngeal anesthesia and potential cardiovascular collapse.
• Dextromethorphan (OTC, 30 mg q6-8h or extended-release): Central cough suppression via NMDA receptor antagonism and sigma-1 receptor activity. No opioid activity at therapeutic doses. Check for concurrent serotonergic medications given risk of serotonin syndrome. Available OTC; no prescription needed.
• Guaifenesin alone (Mucinex, 600–1200 mg q12h ER): Appropriate when expectorant activity is the primary need without cough suppression. OTC, no prescription required, minimal drug interactions.
• Promethazine/codeine (Schedule V): Consider when an antihistamine component is also beneficial (e.g., cough with allergic or post-nasal drip etiology). Note: promethazine carries its own boxed warning and is particularly problematic in patients with COPD or who are at risk for respiratory depression.

Prescribing Considerations Specific to Mar-Cof CG

When prescribing Mar-Cof CG, the following clinical notes are particularly relevant:

• Age restriction: FDA recommends against use in patients under 18 years of age. The risks of respiratory depression in pediatric patients, particularly those who may be CYP2D6 ultra-rapid metabolizers, outweigh the benefits.
• Duration: Prescribe for short-term use only (up to 7 days). A persistent cough beyond 7 days warrants further clinical evaluation.
• Opioid REMS: The FDA requires a Risk Evaluation and Mitigation Strategy (REMS) for all opioid products intended for outpatient use. Counsel patients per REMS requirements on safe use, storage, and disposal.
• Drug interactions: CNS depressants (benzodiazepines, alcohol, other opioids, sleep medications) carry a boxed warning for fatal respiratory depression when combined with codeine. Screen the patient's medication list carefully.

How to Help Patients Find Mar-Cof CG When It's Hard to Fill

Directing patients to medfinder for providers can meaningfully reduce the frustration patients experience when trying to fill a controlled substance prescription. medfinder calls pharmacies on the patient's behalf to identify which ones have a specific medication in stock, then texts the results. This eliminates the time-consuming process of calling multiple pharmacies.

Additionally, consider specifying "brand or generic" on the prescription. Generic codeine phosphate/guaifenesin oral solution (same strength) is manufactured by multiple companies and may be more readily available at pharmacies that don't stock the Mar-Cof CG brand specifically.